Moderna Finds New Legal Chief During Vaccine Rollout

George PaulPeople on the Move
shannon thyme klinger

Shannon Thyme Klinger. Image credit: Novartis

Moderna has named Shannon Thyme Klinger as its new Chief Legal Officer, replacing Lori Henderson who plans to retire later in 2021. When Klinger steps into her new role on June 1, 2021, she will hold a position on Moderna’s Executive Committee and serve as the biotech company’s Corporate Secretary.

“Shannon’s deep global experience in the pharmaceutical industry in both the general counsel and ethics and compliance roles are critical to Moderna as we pivot to a broad international and commercial footprint,” CEO Stéphane Bancel said in a press release.

Klinger joins Moderna after a career at Novartis, where she most recently held the top legal role and served as a member of the Novartis Executive Committee. She also Chief Ethics, Risk & Compliance Officer and Global Head of Litigation, General Counsel, and Global Head of Legal at Novartis’ subsidiary, Sandoz. Before starting her journey at Novartis in 2011, she was a partner at a US-based law firm and held legal and compliance roles at several US-based pharmaceutical and biotech firms.

Klinger said, “I look forward with enthusiasm to joining Moderna and helping continue to build an organization that supports the long-term demands of our evolving business, science, development programs and efforts to bring mRNA medicines to patients.”

When Klinger takes on her new challenge this summer, she won’t be the only new face at Moderna as the company brought on Dr. Corinne Le Goff in mid-January to lead the company’s commercialization efforts.

Based on evidence from clinical trials, the Moderna vaccine has proven to be over 94.5% effective at preventing COVID-19. The vaccine has been approved for use in the US and Europe.

--

The Org is a professional community where transparent companies can show off their team to the world. Join your company here to add yourself to the org chart!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.